GlassScriptPhysician profile
Melissa R Champe-Seagle
NPI 1992797781
$3,293.41
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $834 · 2021: $802 · 2022: $666 · 2023: $376 · 2024: $14.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,028.12 | 2019-2023 | |
| Lilly USA, LLC | $297.48 | 2019-2022 | |
| Novo Nordisk INC | $153.17 | 2019-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.20 | 2019-2023 | Jardiance |
| Ironwood Pharmaceuticals, INC | $145.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $139.67 | 2020-2024 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $136.96 | 2019-2023 | |
| Glaxosmithkline, LLC. | $134.63 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $122.12 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.43 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $83.48 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $81.47 | 2019-2022 | |
| Abbott Laboratories | $71.54 | 2022-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $69.37 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $67.92 | 2021-2023 | Vraylar |
| Ibsa Pharma INC. | $55.43 | 2020-2023 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $48.13 | 2021-2022 | |
| Shield Therapeutics INC | $34.94 | 2023 | Accrufer |
| Allergan, INC. | $29.99 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.43 | 2021 | |
| Dexcom, INC. | $23.49 | 2021 | |
| Exact Sciences Corporation | $22.35 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $20.40 | 2020 | |
| Amgen INC. | $18.93 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.43 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.51 | 2021 | |
| Boston Scientific Corporation | $16.31 | 2019 | |
| Daiichi Sankyo INC. | $16.18 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.90 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.54 | 2019 | |
| Shire North American Group INC | $14.67 | 2019 | |
| Genentech USA, INC. | $11.52 | 2020 | |
| Eisai INC. | $11.08 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Champe-Seagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.